BioVie (BioVie) Debt-to-Asset : 0.48 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is BioVie Debt-to-Asset?

BioVie's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.24 Mil. BioVie's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. BioVie's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $21.49 Mil. BioVie's debt to asset for the quarter that ended in Dec. 2023 was 0.48.

BioVie Debt-to-Asset Historical Data

The historical data trend for BioVie's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Debt-to-Asset Chart

BioVie Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.44

0.61

0.41

BioVie Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.28	0.31	0.41	0.52	0.48

Competitive Comparison of BioVie's Debt-to-Asset

For the Biotechnology subindustry, BioVie's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioVie's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioVie's Debt-to-Asset falls into.

BioVie Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioVie's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.15	+	5.27)	/	35.105
	=	0.41

BioVie's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(10.244	+	0.018)	/	21.49
	=	0.48

BioVie (NAS:BIVI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BioVie Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioVie's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVie (BioVie) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 W Nye Lane, Suite 204, Carson, NV, USA, 89703

Website

https://www.bioviepharma.com

BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Executives

Steve Gorlin	director	150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman	director	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri	director	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim	officer: Chief Financial Officer	C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo	other: Chief Medical Officer	616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams	officer: EVP Liver Cirrhosis Programs	100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham	officer: EVP Liver Cirrhosis R&D	C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading	officer: EVP Neuroscience R&D	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem	officer: EVP of Product Development	5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch	director	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich	director	C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian	officer: Chief Medical Officer	1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486